Efficacy Analysis
EVENTS
The median follow-up period was 93.6 (IQR, 60.9-114.1) months. There were 189 DFS events during the follow-up period, of which 89 were in the EP group and 100 in the EC-P group, respectively. The 5-year DFS for ITT population treated with EP or EC-P was 86.0% vs 80.6%, respectively (HR, 0.82 [95% CI, 0.62-1.10]; noninferior 